Sequana Medical NVSTU:2SE 34 Dividend Payout Ratio is 0.00 as of Jun. 2025. GuruFocus rates STU:2SE with a GF Score™ of 34/100 and a GF Value™ of €0.19 (Significantly Overvalued). The stock has 12 warning signs investors should review. Among 281 Medical Devices & Instruments companies, Sequana Medical NV ranks worse than 355871.53% on this metric.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Sequana Medical NV's Dividend Payout Ratio for the
months ended in Jun. 2025 was 0.00.
The historical rank and industry rank for Sequana Medical NV's Dividend Payout Ratio or its related term are showing as below:
STU:2SE's Dividend Payout Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.42 * Ranked among companies with meaningful Dividend Payout Ratio only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Sequana Medical NV (STU:2SE) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Sequana Medical NV Dividend Payout Ratio Related Terms
Sequana Medical NV Dividend Payout Ratio Historical Data
* Premium members only.
The historical data trend for Sequana Medical NV's Dividend Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2SE vs ABT, SYK, MDT: Dividend Payout Ratio Comparison
For the Medical Devices subindustry, Sequana Medical NV's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sequana Medical NV Dividend Payout Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sequana Medical NV's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where Sequana Medical NV's Dividend Payout Ratio falls into.
Sequana Medical NV Dividend Payout Ratio Calculation
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
Sequana Medical NV's Dividend Payout Ratio for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sequana Medical NV (STU:2SE) has a Dividend Payout Ratio of 0.00 as of Jun. 2025. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Sequana Medical NV and its competitors. According to the industry distribution chart, Sequana Medical NV ranks #999999 out of 281 companies in the Medical Devices & Instruments industry.
Is Sequana Medical NV's Dividend Payout Ratio too high?
Sequana Medical NV's current Dividend Payout Ratio is 0.00. Based on the distribution chart, Sequana Medical NV ranks #999999 out of 281 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sequana Medical NV has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sequana Medical NV's Dividend Payout Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Sequana Medical NV ranks #999999 out of 281 companies for Dividend Payout Ratio. This places Sequana Medical NV in the lower half of its industry. The industry median Dividend Payout Ratio is 0.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Medical Devices & Instruments company?
The median Dividend Payout Ratio among Medical Devices & Instruments companies is 0.42, based on 281 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Sequana Medical NV and its competitors. For the Medical Devices & Instruments industry, the median Dividend Payout Ratio is 0.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sequana Medical NV's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sequana Medical NV stock overvalued right now?
Based on GuruFocus' analysis, Sequana Medical NV (STU:2SE) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.19, compared to a current price of €0.51 — trading 168.9% above its estimated fair value. The current Dividend Payout Ratio is 0.00. Sequana Medical NV's overall GF Score™ is 34/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Sequana Medical NV (STU:2SE), the current Dividend Payout Ratio is 0.00 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sequana Medical NV (STU:2SE) Overvalued in 2026?
Based on GuruFocus' analysis, Sequana Medical NV stock appears to be overvalued.
The current stock price of €0.51 is trading 168.9% above its estimated GF Value™ of €0.19.
GuruFocus considers Sequana Medical NV to be Significantly Overvalued.
Key valuation signals for STU:2SE:
Dividend Payout Ratio: 0.00
GF Value™: €0.19 vs. price of €0.51 (168.9% above fair value)
No single metric tells the full story. See the STU:2SE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sequana Medical NV is a commercial-stage medical device company focused on the development of treatment solutions for the management of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include an alfa pump, which provides a treatment solution for the long-term management of liver refractory ascites and malignant ascites with safety, efficacy, and quality of life benefits demonstrated in multiple clinical studies. The company's geographical segments include Switzerland, Germany, the United Kingdom, France, and the Rest of the world, out of which Germany accounts for the majority of the revenue.
34GF Score
Get the complete analysis for STU:2SE
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2SE has been successfully added to your 
